Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346190 | 0.95 | FFAR1 (0.35) | FFAR1TRPM5KDM1AMAOBSIRT2 | |
| SCHEMBL31345958 | 0.89 | KDM1A (0.38) | FFAR1KDM1ATTRCYP19A1 | |
| SCHEMBL31346125 | 0.89 | KDM1A (0.38) | FFAR1KDM1AMAOBCYP19A1KMT2A | |
| SCHEMBL31346063 | 0.86 | TTR (0.32) | FFAR1TRPM5TTR | |
| SCHEMBL31346096 | 0.84 | FFAR1 (0.40) | FFAR1KDM1AMAOBSIRT2KMT2A | |
| SCHEMBL31346046 | 0.83 | FFAR1 (0.38) | FFAR1MAOB | |
| SCHEMBL31346101 | 0.82 | FFAR1 (0.38) | FFAR1KDM1AMAOB | |
| SCHEMBL31346143 | 0.81 | LDHA (0.46) | TRPM5SIRT2CYP19A1 | |
| SCHEMBL31345983 | 0.80 | ALDH1A1 (0.45) | FFAR1TRPM5MAOBTTRCYP19A1 | |
| SCHEMBL31346122 | 0.78 | AHR (0.33) | TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |